- < General Internal Medicine
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • January 23, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. Epub ahead of print. PMID: 39843940.
Related Posts
GBD 2023 Myocarditis Collaborators. Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023. J Am Coll Cardiol. 2026 Oct 13;88(15):1730-1760. doi: 10.1016/j.jacc.2026.07.039. Epub[...]
Noveir SD, Agrawal N. Moyamoya disease presenting as galactorrhea. JCEM Case Rep. 2026 Oct 13;4(11):luag296. doi: 10.1210/jcemcr/luag296. PMID: 42871260; PMCID: PMC13658269.
Gorsi U, Kumar J, Kim N, Nabavizadeh P, Khan N. ST-Segment Elevation Myocardial Infarction Secondary to Aortic Root Thrombosis in a Patient With a Left[...]
